Until prospective data are available, researchers recommend that patients with ER-low breast cancer “should be counseled regarding the potential benefit” of adjuvant endocrine therapy.

Breast cancer subtyping is essential for determining appropriate treatment strategies, as each molecular category, luminal A, ...

Estrogen receptor alpha (ER), progesterone receptor ... LS specimens from 354 patients for expression of ER, PR, and AR by immunohistochemistry (IHC) using diagnostic-grade reagents and protocols.

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

It is also approved for unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative (immunohistochemistry [IHC] 0, IHC 1+ or IHC 2+/in ...

Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

split between patients with both hormone receptor (HR)-positive and HR-negative disease. Coupled with that large target group of patients is stellar data with Enhertu (trastuzumab deruxtecan ...